#POLB Poolbeg Pharma – Key POLB 002 European Patent Granted

– Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, provides an update on the strengthening of its intellectual property (IP) for its asset POLB 002, a first-in-class, intranasally administered RNA-based immunotherapy for respiratory virus infections.   In January this […]

Open Orphan #ORPH – Proposal to purchase Poolbeg Pharma shares from distribution in specie shareholders

Open Orphan (ORPH) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, notes the announcement dated 11 April 2022 from Poolbeg Pharma plc (“Poolbeg”), regarding a number of new investors (“New Investors”) having expressed interest in acquiring up to £1.6m of […]

#POLB Poolbeg Pharma – Proposal to Purchase Shares from Distribution in Specie Shareholders

Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that a number of new investors (“New Investors”) have expressed interest in acquiring up to £1.6m of Poolbeg Pharma plc shares which are currently locked-up and held in trust by […]

#POLB Poolbeg Pharma – Result of AGM

4 April 2022 – Poolbeg Pharma  (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’) a clinical stage infectious disease pharmaceutical company with a unique capital  light clinical model,  announces that at the Annual General Meeting held at 11:00am today, all resolutions were duly passed with in excess of  99.9% approval. -Ends-   Enquiries   Poolbeg Pharma Plc Jeremy Skillington, CEO Ian […]

#ORPH Open Orphan – £5m RSV human challenge study contract win

Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that hVIVO, a subsidiary of Open Orphan, has signed a £5m respiratory syncytial virus (“RSV”) human challenge study contract with a European biotechnology company (“European biotech”) […]

#POLB Poolbeg Pharma – Artificial Intelligence deal signed with CytoReason

24 March 2022 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, has signed a deal with CytoReason, a leading artificial intelligence (AI) company developing computational disease models for efficient drug discovery and development, to provide AI analysis of Poolbeg’s influenza […]

#POLB Poolbeg Pharma – Final Results

Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’) announces its audited results for the period ended 31 December 2021. These results follow the Company’s spin-out from Open Orphan plc and the subsequent listing on the AIM market of the London Stock Exchange in July 2021.   Poolbeg Pharma is a clinical stage infectious disease pharmaceutical company with a […]

Poolbeg Pharma #POLB – Interview

Co-founder & #COO of One Three Biotech, Brad Pryde catches up with brr mediauk on the #AI Deal with #POLB Poolbeg Pharma to identify new #drugs & treatments for #RSV.     https://www.youtube.com/watch?v=TnKrI6xCt4s&ab_channel=PoolbegPharma

#POLB Poolbeg Pharma – Notice of Results

Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’) a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model , will announce its results for the period ended 31 December 2021 on Thursday 3 March 2022. The Company will be hosting an online presentation for investors on the same day, at 6:00pm GMT on the Investor […]